Business
Lodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World's Leading Health Forums
Lodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World's Leading Health Forums.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nLodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World's Leading Health Forums\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nLodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World's Leading Health Forums\nPR Newswire\nORLANDO, Fla., May 19, 2016\n\n\n\n\n \n\n \n\n\nORLANDO, Fla., May 19, 2016 /PRNewswire/ -- Immune Therapeutics, Inc. (O\n\n TCQB: IMUN\n ), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, such as HIV/AIDS and cancer, with a focus on emerging nations, today announced its attendance at the 69th World Health Assembly (\n \"\n WHA\n \"\n ) in Geneva, Switzerland to promote LodonalTM.\n \n\nThe WHA is the decision-making body of the World Health Organization (\"WHO\"). It is attended by delegations from all WHO member states and focuses on a specific health agenda prepared by the executive board. The main functions of the WHA are to determine the policies of the organization, appoint the Director-General, supervise financial policies, and review and approve the proposed programme budget (www.who.int/mediacentre/events/2016/wha69/en/).\n\nIn association with The Business Council for International Understanding (BCIU) and GB Pharma Holdings, Immune Therapeutics, Inc. (\"Immune Therapeutics\") is hosting a welcome reception on Monday, May 23rd in Geneva, Switzerland at the WHA.  Guests will include leadership from the U.S. & Foreign Health Delegations and Corporate Stakeholders.  During and following this event, Immune Therapeutics and GB Pharma Holdings will focus on engaging with the heads of delegations representing primary targets for distribution of LodonalTM. \n\n\"Following successful achievement of two major milestones for LodonalTM in Nigeria this year, we are going to the WHA next week with momentum,\" said Noreen Griffin, Chief Executive Officer of Immune Therapeutics. \n\nEarlier this year Immune Therapeutics announced its clinical study in ...